Literature DB >> 15566889

IgG subclass response to human parvovirus B19 infection.

R Franssila1, M Söderlund, C S Brown, W J Spaan, I Seppälä, K Hedman.   

Abstract

BACKGROUND: IgG antibodies are essential to immunity against human parvovirus B19 and can neutralize infection both in bone marrow cell cultures infected in vitro and in chronically infected immunosuppressed individuals.
OBJECTIVES: To assess the levels and response kinetics of IgG subclasses towards individual structural proteins of human parvovirus B19. STUDY
DESIGN: Subclasses of IgG for capsid proteins VP1 or VP2 were quantified by EIA using monoclonal antibodies in 30 acutely infected and 30 convalescent patients, as well as in 32 remotely infected and 20 non-infected controls.
RESULTS: In all groups of seropositive individuals the predominant subclass for either structural protein was IgG1. Subclass IgG3 was associated with acute infection. By contrast, IgG4 appeared months after infection, and occurred specifically towards VP1. The ratio of VP1-specific subclasses IgG3 and IgG4 provided a diagnostic test for recent infection with a specificity of 98% and a sensitivity of 97%.
CONCLUSIONS: Comparative measurement of VP1-specific IgG3 and IgG4 is useful in diagnosis. The IgG4 results point to long-term expression of immunologically active VP1 and to T-cell help of T(h)2 type for B-cells recognizing VP1.

Entities:  

Year:  1996        PMID: 15566889     DOI: 10.1016/0928-0197(96)00156-0

Source DB:  PubMed          Journal:  Clin Diagn Virol        ISSN: 0928-0197


  10 in total

1.  Comparison of a baculovirus-based VP2 enzyme immunoassay (EIA) to an Escherichia coli-based VP1 EIA for detection of human parvovirus B19 immunoglobulin M and immunoglobulin G in sera of pregnant women.

Authors:  J A Jordan
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

2.  Impaired gamma interferon responses against parvovirus B19 by recently infected children.

Authors:  A Corcoran; S Doyle; D Waldron; A Nicholson; B P Mahon
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Comparison of three commercially available serologic assays used to detect human parvovirus B19-specific immunoglobulin M (IgM) and IgG antibodies in sera of pregnant women.

Authors:  Allyson R Butchko; Jeanne A Jordan
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

4.  T helper cell-mediated interferon-gamma expression after human parvovirus B19 infection: persisting VP2-specific and transient VP1u-specific activity.

Authors:  R Franssila; J Auramo; S Modrow; M Möbs; C Oker-Blom; P Käpylä; M Söderlund-Venermo; K Hedman
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

5.  Acute-phase-specific heptapeptide epitope for diagnosis of parvovirus B19 infection.

Authors:  L Kaikkonen; H Lankinen; I Harjunpää; K Hokynar; M Söderlund-Venermo; C Oker-Blom; L Hedman; K Hedman
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

Review 6.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

7.  Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1.

Authors:  Declan Madsen; Emma R Cantwell; Timothy O'Brien; Patricia A Johnson; Bernard P Mahon
Journal:  J Gen Virol       Date:  2009-07-29       Impact factor: 3.891

8.  Diverse IgG subclass responses to adeno-associated virus infection and vector administration.

Authors:  Samuel L Murphy; Hojun Li; Federico Mingozzi; Denise E Sabatino; Daniel J Hui; Shyrie A Edmonson; Katherine A High
Journal:  J Med Virol       Date:  2009-01       Impact factor: 2.327

Review 9.  Cytokines in parvovirus B19 infection as an aid to understanding chronic fatigue syndrome.

Authors:  Jonathan R Kerr; David A J Tyrrell
Journal:  Curr Pain Headache Rep       Date:  2003-10

10.  Comparison of tissue distribution, persistence, and molecular epidemiology of parvovirus B19 and novel human parvoviruses PARV4 and human bocavirus.

Authors:  Ashleigh Manning; Samantha J Willey; Jeanne E Bell; Peter Simmonds
Journal:  J Infect Dis       Date:  2007-03-21       Impact factor: 5.226

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.